Debbie Rigby takes a look at the latest research news
In this large double-blind event-driven trial, ticagrelor (90 mg twice daily) was not shown to be superior to clopidogrel (75 mg once daily) for the reduction of cardiovascular events in patients with symptomatic peripheral artery disease. Major bleeding occurred at similar rates among the patients in the two trial groups.
New Engl J Med, November 13, 2016
This update to the 2008 US Preventive Services Task Force (USPSTF) statement on screening for lipid disorders in adults recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors (dyslipidaemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of 10% or greater. The article also concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use in adults 76 years and older.
Meta-analyses of randomised controlled trials (RCTs) show that vitamin D supplementation alone does not improve musculoskeletal outcomes. Meta-analyses of randomised controlled trials of vitamin D on non-musculoskeletal outcomes suggest ongoing uncertainty. Low dose vitamin D supplements (400-800 IU/day) can be considered on an individual basis for people at high risk of deficiency.
A meta-analysis of prospective cohort studies has concluded that prediabetes, defined as impaired glucose tolerance, impaired fasting glucose, or raised HbA1c, is associated with an increased risk of cardiovascular disease. The health risk might be increased in people with a fasting glucose concentration as low as 5.6 mmol/L or HbA1c of 39 mmol/mol.